Phase II trial of pembrolizumab in patients with platinum refractory germ-cell tumors: a Hoosier Cancer Research Network Study GU14-206
2017 · Annals of Oncology · 191 citations
https://doi.org/10.1093/annonc/mdx680
N
Nasser H. Hanna
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
470
Papers
16.4K
Citations
59
h-index
160
i10-index
Nasser H. Hanna is an academic researcher from Indiana University School of Medicine. The author has contributed to research in topics: Lung Cancer Treatments and Mutations & Lung Cancer Research Studies & Lung Cancer Diagnosis and Treatment. The author has an h-index of 59, co-authored 400 publications.
ORCID: 0000-0002-7046-6426Papers by this author
worksUnderstanding lung cancer screening behavior: Racial, gender, and geographic differences among Indiana long-term smokers
2018 · Preventive Medicine Reports · 101 citations
https://doi.org/10.1016/j.pmedr.2018.01.018
Recent issues in first-line treatment of advanced non-small-cell lung cancer: Results of an International Expert Panel Meeting of the Italian Association of Thoracic Oncology
2009 · Lung Cancer · 70 citations
https://doi.org/10.1016/j.lungcan.2009.11.018
Time since start of first-line therapy as a predictive clinical marker for nintedanib in patients with previously treated non-small cell lung cancer
2017 · ESMO Open · 9 citations
https://doi.org/10.1136/esmoopen-2016-000102
Evaluation of Radiation Pneumonitis in a Phase 2 Study of Consolidation Immunotherapy With Nivolumab and Ipilimumab or Nivolumab Alone Following Concurrent Chemoradiation Therapy for Unresectable Stage IIIA/IIIB Non-Small Cell Lung Cancer
2024 · International Journal of Radiation Oncology*Biology*Physics · 6 citations
https://doi.org/10.1016/j.ijrobp.2024.09.050
Randomized phase II study of consolidation immunotherapy with nivolumab and ipilimumab or nivolumab alone following concurrent chemoradiotherapy for unresectable stage IIIA/IIIB non-small-cell lung cancer (NSCLC): Big Ten Cancer Research Consortium LUN16-081
2025 · Journal for ImmunoTherapy of Cancer · 6 citations
https://doi.org/10.1136/jitc-2024-010316
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat